A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms SOLACE-kids
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 May 2019 Planned End Date changed from 28 Apr 2022 to 22 Aug 2022.
- 14 May 2019 Planned primary completion date changed from 1 Apr 2019 to 31 Dec 2020.
- 06 Dec 2018 Planned End Date changed from 30 Mar 2022 to 28 Apr 2022.